Breukelen, Netherlands

Louis Hartog Cohen


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • NL-3621 HR Breukelen, NL (1999)
  • Breukelen, NL (1998 - 2003)

Company Filing History:


Years Active: 1998-2003

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Louis Hartog Cohen: Innovator in Prenyl Transferase Inhibition

Introduction

Louis Hartog Cohen is a notable inventor based in Breukelen, Netherlands. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for prenylated pyrophosphate-consuming enzymes. With a total of 4 patents to his name, Cohen's work has implications for various therapeutic applications.

Latest Patents

Cohen's latest patents include innovative peptide-like FPP-analogues that are designed to inhibit protein:prenyl transferases. These enzymes, such as protein:geranylgeranyl transferase-1, play a crucial role in cellular processes. His patents also cover inhibitors for other prenyl pyrophosphate-consuming enzymes, including squalene synthase and geranylgeranyl pyrophosphate synthase. These advancements highlight his commitment to addressing complex biochemical challenges.

Career Highlights

Throughout his career, Cohen has worked with esteemed organizations, including the Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek. His research has contributed to a deeper understanding of enzyme inhibition and its potential therapeutic benefits. His innovative approaches have positioned him as a key figure in his field.

Collaborations

Cohen has collaborated with notable colleagues such as Gijsbert Arie Van Der Marel and Jacobus Hubertus Van Boom. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Louis Hartog Cohen's contributions to the field of biochemistry through his patents and collaborations underscore his role as an influential inventor. His work continues to pave the way for advancements in enzyme inhibition and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…